Trump’s NIH And NSF Cuts Estimated To Cost The U.S. Economy $10 Billion Annually

Proposed FY2026 budget cuts to fundamental science, including $18 billion from the NIH and $5 billion from the NSF, are projected to negatively impact long-term U.S. economic growth, despite appearing fiscally responsible in the short term. Macro-empirical research indicates that every dollar invested in non-defense public R&D yields $1.40–$2.10 in economic output, and these cuts would eventually strip at least $10 billion per year from U.S. output due to the under-provision of basic research by the private sector and the long-term impact of public science on productivity.

Analysis

Proposed FY2026 budget cuts, notably $18 billion from the National Institutes of Health (NIH) and $5 billion from the National Science Foundation (NSF), totaling $23 billion, present a significant threat to America’s long-term economic growth and innovation capacity, eliciting a strongly negative sentiment. New macro-empirical research by Fieldhouse and Mertens indicates that every dollar of non-defense public R&D yields $1.40–$2.10 in economic output, with their preferred model suggesting a 171% return, substantially exceeding returns on private R&D (approx. 55%) and public infrastructure (approx. 9.2%). These proposed cuts are projected to strip at least $10 billion annually from U.S. output, translating to a net economic loss of between $9.2 billion and $16 billion. The rationale for public funding stems from market failure, as basic research generates 'knowledge spillovers' that benefit society broadly but are difficult for individual firms to monetize, leading to private sector underinvestment; private companies direct only 6 cents of every R&D dollar to basic research, versus 34 cents for public non-defense R&D. Government funding has historically driven about 20% of U.S. productivity, and public R&D also 'crowds in' private investment, with every public dollar stimulating an additional $0.20 in private R&D, and $1.46 in non-defense structures over eight years. The economic benefits of public R&D, while substantial, typically take 8-10 years to materialize and 14 years to reach peak impact on productivity, a timeline that misaligns with political cycles, often leading to underfunding despite the research being effectively self-financing from a fiscal perspective. The market impact score of 0.5 suggests these long-term consequences may not be immediately priced in by markets.

Key Decisions for Investors

• Investors should closely monitor the progression of the proposed FY2026 budget cuts to the NIH and NSF, as their enactment could significantly dampen long-term U.S. productivity growth and innovation, potentially impacting broad market returns and the competitiveness of R&D-intensive sectors.
• Consider the extended timeline for impact, as reduced public funding for basic research may introduce headwinds for sectors like biotechnology, pharmaceuticals, advanced materials, and emerging technologies, potentially affecting their innovation pipelines and growth trajectories 8-14 years out.
• Evaluate potential shifts in global R&D investment attractiveness and leadership if U.S. public science funding diminishes, recognizing that the private sector is unlikely to fully compensate for the reduction in foundational research, thereby creating a net drag on overall innovation.